![]()
11.09.20151385
At 5 years, patients with paroxysmal atrial fibrillation assigned catheter ablation were more likely to be free from recurrent atrial fibrillation than those assigned antiarrhythmic drugs, according to new data from the MANTRA-PAF study.
![]()
09.09.20151374
New Haven Pharmaceuticals announced FDA approval of its extended-release aspirin capsules for the secondary prevention of stroke and acute cardiac events in high-risk patients, according to a press release.
![]()
08.09.20151627
Even without accompanying metabolic dysfunction, adiposity appears to be a risk factor for type 2 diabetes, according to recent findings.
![]()
07.09.20151303
The study evaluated the safety and efficacy of a regimen of P2Y12 inhibitor cangrelor followed by clopidogrel compared with clopidogrel alone in patients who underwent PCI with transradial or transfemoral access.
![]()
04.09.20151483
AstraZeneca announced that a 60 mg twice-daily dose of its antiplatelet agent ticagrelor has been approved by the FDA for prevention of CV death, MI and stroke in patients more than 1 year after an ACS event.
![]()
03.09.20151626
The early addition of aldosterone inhibition to standard care for patients with acute MI without HF did not reduce the risk for adverse outcomes, according to results from the ALBATROSS study presented at the European Society of Cardiology Congress.
![]()
02.09.20151871
Chief Medical Editor of Cardiology Today’s Intervention, discusses results of the OPTIDUAL Hot Line trial of dual antiplatelet therapy after drug-eluting stent implantation and provides his opinion on future research to determine the optimal duration of therapy in this population.
